Cargando…

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies

The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Rujas, Edurne, Cui, Hong, Sicard, Taylor, Semesi, Anthony, Julien, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545189/
https://www.ncbi.nlm.nih.gov/pubmed/33033255
http://dx.doi.org/10.1038/s41467-020-18828-4
_version_ 1783591984053616640
author Rujas, Edurne
Cui, Hong
Sicard, Taylor
Semesi, Anthony
Julien, Jean-Philippe
author_facet Rujas, Edurne
Cui, Hong
Sicard, Taylor
Semesi, Anthony
Julien, Jean-Philippe
author_sort Rujas, Edurne
collection PubMed
description The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade. Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution. A central FDPPPF motif and residues within the CC’ loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members. Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding. In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy. Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities. Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
format Online
Article
Text
id pubmed-7545189
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75451892020-10-19 Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies Rujas, Edurne Cui, Hong Sicard, Taylor Semesi, Anthony Julien, Jean-Philippe Nat Commun Article The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade. Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution. A central FDPPPF motif and residues within the CC’ loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members. Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding. In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy. Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities. Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors. Nature Publishing Group UK 2020-10-08 /pmc/articles/PMC7545189/ /pubmed/33033255 http://dx.doi.org/10.1038/s41467-020-18828-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Rujas, Edurne
Cui, Hong
Sicard, Taylor
Semesi, Anthony
Julien, Jean-Philippe
Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title_full Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title_fullStr Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title_full_unstemmed Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title_short Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
title_sort structural characterization of the icos/icos-l immune complex reveals high molecular mimicry by therapeutic antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545189/
https://www.ncbi.nlm.nih.gov/pubmed/33033255
http://dx.doi.org/10.1038/s41467-020-18828-4
work_keys_str_mv AT rujasedurne structuralcharacterizationoftheicosicoslimmunecomplexrevealshighmolecularmimicrybytherapeuticantibodies
AT cuihong structuralcharacterizationoftheicosicoslimmunecomplexrevealshighmolecularmimicrybytherapeuticantibodies
AT sicardtaylor structuralcharacterizationoftheicosicoslimmunecomplexrevealshighmolecularmimicrybytherapeuticantibodies
AT semesianthony structuralcharacterizationoftheicosicoslimmunecomplexrevealshighmolecularmimicrybytherapeuticantibodies
AT julienjeanphilippe structuralcharacterizationoftheicosicoslimmunecomplexrevealshighmolecularmimicrybytherapeuticantibodies